Skip to main content
Erschienen in: International Journal of Hematology 4/2017

13.06.2017 | Original Article

Prevalence and clinical outcomes of hepatitis B virus infection in patients with aplastic anemia

verfasst von: Pan Zhao, Qing Gao, Qiulian He, Jing Tan

Erschienen in: International Journal of Hematology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

The association of HBV infection with other hematopoietic diseases has been discussed previously. However, the clinical significance and clinical outcomes of HBV infection in AA patients have not been clarified. In this study, we sought to investigate the prevalence and related events of HBV in patients with AA who received immunosuppressive therapy. We retrospectively analyzed 245 patients with acquired AA. The HBsAg positivity rate was 14.69% in this group of AA patients. No significant difference was observed in the severity of AA patients with HBV infection and in those without (P = 0.6358). HBV reactivation occurred in 4.76% of HBsAg-positive patients who received ATG/ALG + CsA treatment without anti-viral prophylaxis. HBV-infected patients who received CsA alone did not develop reactivation. Patients with HBV reactivation showed favorable clinical outcomes, with no HBV-related deaths. There was no significant difference in overall probability of survival in patients with different HBV infection status (P = 0.8617). Given the low rate of reactivation and favorable outcomes after reactivation in AA patients, close monitoring of HBV DNA, hepatic function and patient immune status may be a more effective approach than routine prophylaxis for AA patients with HBV infection undergoing ATG/ALG + CsA treatment. Further studies are warranted to clarify the optimal time to initiate anti-viral treatment.
Literatur
1.
Zurück zum Zitat Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44.CrossRefPubMed Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44.CrossRefPubMed
3.
Zurück zum Zitat Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma. Ann Hematol. 2008;87:475–80.CrossRefPubMed Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma. Ann Hematol. 2008;87:475–80.CrossRefPubMed
4.
Zurück zum Zitat Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11:827–34.CrossRefPubMedPubMedCentral Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11:827–34.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Huang B, Li J, Zhou Z, Zheng D, Liu J, Chen M. High prevalence of hepatitis B virus infection in multiple myeloma. Leuk Lymphoma. 2012;53:270–4.CrossRefPubMed Huang B, Li J, Zhou Z, Zheng D, Liu J, Chen M. High prevalence of hepatitis B virus infection in multiple myeloma. Leuk Lymphoma. 2012;53:270–4.CrossRefPubMed
8.
Zurück zum Zitat International Agranulocytosis and Aplastic Anemia Study. Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood. 1987;70:1718–21. International Agranulocytosis and Aplastic Anemia Study. Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood. 1987;70:1718–21.
9.
Zurück zum Zitat Guinan EC. Diagnosis and management of aplastic anemia. Hematol Am Soc Hematol Educ Program. 2011;2011:76–81. Guinan EC. Diagnosis and management of aplastic anemia. Hematol Am Soc Hematol Educ Program. 2011;2011:76–81.
10.
Zurück zum Zitat Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31:1169–75.CrossRefPubMed Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31:1169–75.CrossRefPubMed
11.
Zurück zum Zitat Marsh JCW, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Hematol. 2009;147:43–70.CrossRef Marsh JCW, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Hematol. 2009;147:43–70.CrossRef
12.
Zurück zum Zitat Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Reprint of: epidemiological serosurvey of Hepatitis B in China—declining HBV prevalence due to Hepatitis B vaccination. Vaccine. 2013;31(Suppl 9):J21–8.CrossRefPubMed Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Reprint of: epidemiological serosurvey of Hepatitis B in China—declining HBV prevalence due to Hepatitis B vaccination. Vaccine. 2013;31(Suppl 9):J21–8.CrossRefPubMed
13.
Zurück zum Zitat Smith PR, Zampino R, Gutteridge C, Karayiannis P, Aitken C. Reactivation of precore variant hepatitis B virus in a child with severe aplastic anaemia. J Med Virol. 2001;65:470–2.CrossRefPubMed Smith PR, Zampino R, Gutteridge C, Karayiannis P, Aitken C. Reactivation of precore variant hepatitis B virus in a child with severe aplastic anaemia. J Med Virol. 2001;65:470–2.CrossRefPubMed
14.
Zurück zum Zitat Dai MS, Kao WY, Shyu RY, Chao TY. Restoration of immunity and reactivation of hepatitis B virus after immunosuppressive therapy in a patient with severe aplastic anaemia. J Viral Hepat. 2004;11:283–5.CrossRefPubMed Dai MS, Kao WY, Shyu RY, Chao TY. Restoration of immunity and reactivation of hepatitis B virus after immunosuppressive therapy in a patient with severe aplastic anaemia. J Viral Hepat. 2004;11:283–5.CrossRefPubMed
16.
Zurück zum Zitat Xie HY, Xia WL, Zhang CC, Wu LM, Ji HF, Cheng Y, et al. Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment. Acta Pharmacol Sin. 2007;28:975–84.CrossRefPubMed Xie HY, Xia WL, Zhang CC, Wu LM, Ji HF, Cheng Y, et al. Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment. Acta Pharmacol Sin. 2007;28:975–84.CrossRefPubMed
17.
Zurück zum Zitat Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood. 2007;109:3219–24.CrossRefPubMedPubMedCentral Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood. 2007;109:3219–24.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Chen J, Wang J, Yang J, Zhang W, Song X, Chen L. Concurrent infection of hepatitis B virus negatively affects the clinical outcome and prognosis of patients with non-Hodgkin’s lymphoma after chemotherapy. PLoS One. 2013;8:e69400.CrossRefPubMedPubMedCentral Chen J, Wang J, Yang J, Zhang W, Song X, Chen L. Concurrent infection of hepatitis B virus negatively affects the clinical outcome and prognosis of patients with non-Hodgkin’s lymphoma after chemotherapy. PLoS One. 2013;8:e69400.CrossRefPubMedPubMedCentral
19.
20.
Zurück zum Zitat EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRef EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRef
21.
Zurück zum Zitat Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–61.CrossRefPubMed Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–61.CrossRefPubMed
22.
Zurück zum Zitat Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90:1219–23.CrossRefPubMed Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90:1219–23.CrossRefPubMed
Metadaten
Titel
Prevalence and clinical outcomes of hepatitis B virus infection in patients with aplastic anemia
verfasst von
Pan Zhao
Qing Gao
Qiulian He
Jing Tan
Publikationsdatum
13.06.2017
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2276-3

Weitere Artikel der Ausgabe 4/2017

International Journal of Hematology 4/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.